Key result
Adjusted-dose LMWH was associated with a higher rate of in-hospital all-cause death but a lower risk of in-hospital bleeding compared to conventional dose in patients with acute pulmonary embolism and renal insufficiency.
Why the study?
Renal function is associated with prognoses for acute pulmonary embolism, prompting investigation into anticoagulant use, LMWH dosing, and in-hospital outcomes in patients with renal insufficiency.
Does adjusted dose LMWH reduce in-hospital bleeding or mortality compared to conventional dose LMWH in patients with acute pulmonary embolism and renal insufficiency?
Cohort (n=5,870)
Yes
Does adjusted dose LMWH reduce in-hospital bleeding or mortality compared to conventional dose LMWH in patients with acute pulmonary embolism and renal insufficiency?
In real-world practice, adjusting LMWH dosage for acute pulmonary embolism patients with renal insufficiency is associated with a significantly lower risk of in-hospital bleeding.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for adjusted LMWH dosing in renal insufficiency; prospective trials needed before clinical adoption.
BACKGROUND: Renal function is associated with prognoses for acute pulmonary embolism (PE). OBJECTIVE: To investigate the application of anticoagulants and dosage of LMWH among patients with renal insufficiency (RI), and the association between LWMH dosage and the patients' in-hospital outcomes. METHODS: Adult patients diagnosed with non-high risk acute PE from 2009 to 2015, with available data of creatinine clearance (CCr) were enrolled from a multicenter registry in China. Renal insufficiency (RI) was defined as CCr < 60 ml/min. LMWH dosage was converted into IU/kg daily dose and presented as adjusted dose (≤ 100 IU/kg/day) and conventional dose (> 100 IU/kg/day). All-cause death, PE-related death and bleeding events during hospitalization were analyzed as endpoints. RESULTS: Among the enrolled 5870 patients, RI occurred in 1311 (22.3%). 30 ≤ CCr < 60 ml/min was associated with higher rate of bleeding events and CCr < 30 ml/min was associated with all-cause death, PE-related death and major bleeding. Adjusted-dose LMWH was applied in 26.1% of patients with 30 ≤ CCr < 60 ml/min and in 26.2% of CCr < 30 ml/min patients. Among patients with RI, in-hospital bleeding occurred more frequently in those who were administered conventional dose of LMWH, compared with adjusted dose (9.2% vs 5.0%, p = 0.047). Adjusted dose of LMWH presented as protective factor for in-hospital bleeding (OR 0.62, 95%CI 0.27-1.00, p = 0.0496) and the risk of bleeding increased as length of hospital stay prolonged (OR 1.03, 95%CI 1.01-1.06, p = 0.0014). CONCLUSIONS: The proportion of adjusted usage of LMWH was low. The application of adjusted-dose LMWH was associated with lower risk of in-hospital bleeding for RI patients, in real-world setting of PE treatment. Anticoagulation strategy for RI patients should be paid more attention and requires evidence of high quality. TRIAL REGISTRATION: The CURES was registered in ClinicalTrias.gov, identifier number: NCT02943343 .
No takes yet. Share an insight, caveat, or question.
Wang et al. (2022) conducted a cohort in Acute pulmonary embolism with renal insufficiency (n=5,870). Adjusted dose LMWH (≤ 100 IU/kg/day) vs. Conventional dose LMWH (> 100 IU/kg/day) was evaluated on In-hospital all-cause death (p=0.0434). Adjusted-dose LMWH was associated with a higher rate of in-hospital all-cause death but a lower risk of in-hospital bleeding compared to conventional dose in patients with acute pulmonary embolism and renal insufficiency.
Synapse has enriched 10 related papers. Consider them for comparative context: